Interferon therapy for lymphoproliferative disorders.
作者信息
Roth M S, Bunn P A, Foon K A
出版信息
Cancer Treat Res. 1988;38:231-52. doi: 10.1007/978-1-4613-1713-5_7.
PMID:2484433
Abstract
摘要
相似文献
1
Interferon therapy for lymphoproliferative disorders.用于淋巴增殖性疾病的干扰素治疗。
Cancer Treat Res. 1988;38:231-52. doi: 10.1007/978-1-4613-1713-5_7.
2
Biological molecules in the treatment of hematological disorders.
Sangre (Barc). 1989 Feb;34(1):53-8.
3
Recombinant alpha-interferons, thyroid irradiation and thyroid disease.重组α干扰素、甲状腺照射与甲状腺疾病
Acta Haematol. 1991;85(3):160-3. doi: 10.1159/000204881.
4
Biotherapy of chronic myelogenous leukemia with interferon.
Semin Oncol. 1988 Oct;15(5 Suppl 5):14-20.
5
[Interferon and chronic myeloid leukemia].[干扰素与慢性粒细胞白血病]
Sangre (Barc). 1990 Jun;35(3):213-7.
6
A dual anti-tumor effect of a combination of interferon-alpha and 5-flurouracil or 2-chlorodeoxyadenosine on natural killer (NK) cell mediated cytotoxicity.干扰素-α与5-氟尿嘧啶或2-氯脱氧腺苷联合使用对自然杀伤（NK）细胞介导的细胞毒性的双重抗肿瘤作用。
Adv Exp Med Biol. 1991;309A:69-73. doi: 10.1007/978-1-4899-2638-8_15.
7
The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes.干扰素（IFN）-α在慢性粒细胞白血病（CML）衍生细胞系中的抗肿瘤活性取决于IFN-α亚型。
Cancer Lett. 2002 Nov 28;185(2):173-9. doi: 10.1016/s0304-3835(02)00277-x.
8
Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.缓解期慢性髓性白血病患者中干扰素和白细胞介素-2对自然杀伤细胞及抗体依赖性细胞毒性的调节作用
Oncology. 1989;46(2):123-7. doi: 10.1159/000226698.
9
alpha-Interferon in hematological malignancies.α干扰素在血液系统恶性肿瘤中的应用
Curr Opin Biotechnol. 1991 Dec;2(6):847-50. doi: 10.1016/s0958-1669(05)80119-3.
10
Interferons for the treatment of hematological malignancies.用于治疗血液系统恶性肿瘤的干扰素。
Oncology. 1994 Mar-Apr;51(2):137-41. doi: 10.1159/000227328.
引用本文的文献
1
Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.接受重组人干扰素-α 2a和白细胞介素-2门诊细胞因子介导免疫治疗的血液系统恶性肿瘤患者的免疫学评估
Cancer Immunol Immunother. 1992;35(6):401-11. doi: 10.1007/BF01789019.
Zotero 插件